ArticleScience translational medicine2017
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers.
Erratum issuedAbstract read
In one paragraph
Article in Science translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 95 papers.
0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed
12.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 148 citations in OpenAlex.
- The neural stem cell‑NSCLC axis: Molecular drivers, microenvironment crosstalk and emerging therapies (Review).International journal of oncology · 2026Review
- Molecular mechanisms and therapeutic targets in lung cancer-nerve crosstalk.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Metabolic Crosstalk Between Host and Tumor as a Circuit of Resilience in Cancer Therapy.Cells · 2026Review
- Cancer Neoaxonogenesis: Mechanisms and Factors Involved in the Recruitment of Peripheral Nerves by Cancer Tissue.International journal of molecular sciences · 2026Review
- IL‑6: A key player in the EGFR‑TKI‑resistant tumor microenvironment and its therapeutic implications (Review).International journal of oncology · 2026Review
- Article
- Stress Biology in Cancer: Neuroendocrine-Immune Mechanisms Linking Tumor Progression to Translational Interventions.Cancer communications (London, England) · 2026Review
- Prognostic value of emotional distress in advanced non-small cell lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Article
- The crosstalk between nerves and immunity: chronic stress as a driver of tumor progression.Frontiers in immunology · 2026Review
- Fucoidan for Lung Cancer Therapy: A Review of Classification, Mechanisms, and Preclinical Studies.ACS omega · 2025Review
- Neural regulation of lung cancer: from mechanisms to clinical implications.European journal of medical research · 2025Review
- The Activity of EGFR CAR NK and CAR T Cells against EGFR Inhibitor-Resistant NSCLC and Drug-Tolerant Persister Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer.Molecular cancer · 2025Article
- C1orf116 inhibits acquired resistance to EGFR inhibitors in EGFR mutant lung adenocarcinoma by suppressing the ATM/ATR pathways.Translational lung cancer research · 2025Article
- Tumor microenvironment in osteosarcoma: From cellular mechanism to clinical therapy.Genes & diseases · 2025Review
- Chronic stress: a fourth etiology in tumorigenesis?Molecular cancer · 2025Review
- Cancer and neurotransmitter receptors.Chinese medical journal · 2025Review
- S- and R-Carvedilol Prevent Benzo(a)pyrene-Induced Lung Carcinogenesis.Thoracic cancer · 2025Article
- AHSA1-HSP90AA1 complex stabilized IFI6 and TGFB1 promotes mitochondrial stability and EMT in EGFR-mutated lung adenocarcinoma under Osimertinib pressure.Cell death & disease · 2025Article
- Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
25 authors at 6 institutions in 3 countries.
Monique B NilssonDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID http://orcid.org/0000-0002-0975-8833
Huiying SunDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID http://orcid.org/0000-0001-8916-9387
Lixia DiaoDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID http://orcid.org/0000-0001-6995-4492
Pan TongDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Diane LiuDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID http://orcid.org/0000-0002-7459-1769
Lerong LiDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Youhong FanDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Alissa PoteeteDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID http://orcid.org/0000-0002-6091-2840
Seung-Oe LimDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID http://orcid.org/0000-0002-8138-4549
Kathryn HowellsAstraZeneca, Melbourn, SG8 6EE, UK.
Vincent HaddadAstraZeneca, Melbourn, SG8 6EE, UK.ORCID http://orcid.org/0000-0001-8290-2443
Daniel GomezDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hai TranDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Guillermo Armaiz PenaDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Lecia V SequistMassachusetts General Hospital Cancer Center, Boston, MA 02114, USA.ORCID http://orcid.org/0000-0002-8965-6991
James C YangGraduate Institute of Oncology, National Taiwan University and National Taiwan University Hospital, Taipei City 100, Taiwan.ORCID http://orcid.org/0000-0002-5586-5138
Jing WangDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Edward S KimSolid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute Carolinas HealthCare System, Charlotte, NC 28204, USA.ORCID http://orcid.org/0000-0001-8351-1196
Roy HerbstSection of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, Yale, New Haven, CT 06510, USA.
J Jack LeeDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID http://orcid.org/0000-0001-5469-9214
Waun Ki HongDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ignacio WistubaDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID http://orcid.org/0000-0003-3365-6340
Mien-Chie HungDepartment of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID http://orcid.org/0000-0003-4317-4740
Anil K SoodDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
John V HeymachDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. jheymach@mdanderson.org.ORCID http://orcid.org/0000-0001-9068-8942
The University of Texas MD Anderson Cancer Center · USMelbourn Science Park · GBCarolinas Healthcare System · USMassachusetts General Hospital · USNational Taiwan University Hospital · TWSmilow Cancer Hospital · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MUNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4MOvarian Cancer: Mechanisms of Neuroendocrine RegulationR01CA109298 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2005 to 2017
$4.5MOvercoming Resistance to Anti-EGFR Therapy by Drug RepurposingR01CA190628 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FANG, BINGLIANG, HEYMACH, JOHN V. · 2015 to 2019
$2.6MNCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA109298NCI NIH HHS R01 CA190628
Abstract
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance mediated by T790M-independent mechanisms remains a major challenge in the treatment of non-small cell lung cancer (NSCLC). We identified a targetable mechanism of EGFR inhibitor resistance whereby stress hormones activate β
Indexed as
Adrenergic beta-AntagonistsAfatinibAMP-Activated Protein Kinase KinasesCarcinoma, Non-Small-Cell LungCell Line, TumorCyclic AMP Response Element-Binding ProteinDrug Resistance, NeoplasmEpinephrineErbB ReceptorsHumansInterleukin-6Lung NeoplasmsMutationNorepinephrineProtein Kinase CProtein Kinase InhibitorsAdrenergic beta-AntagonistsAfatinibAMP-Activated Protein Kinase KinasesCyclic AMP Response Element-Binding ProteinEpinephrineErbB ReceptorsInterleukin-6NorepinephrineProtein Kinase CProtein Kinase InhibitorsProtein Serine-Threonine KinasesQuinazolinesReceptors, Adrenergic, betaSTK11 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.